




Article

Evaluation of Biochemical and Oxidative Stress Markers in the Early Stages of Rheumatoid Arthritis in a Comparative Study of Two Different Therapeutic Approaches

Stavroula Ioannidou ¹, Athanasia Tsiakalidou ¹, Konstantina Kazeli ^{1,2}, Argyrios Ginoudis ³, Ariadne Fouza ⁴, Maria Daoudaki ⁵ and Evgenia Lymperaki ^{1,*}

- ¹ Department of Biomedical Sciences, International Hellenic University, 57400 Thessaloniki, Greece; stayroyla.ioannidou@gmail.com (S.I.); tsiakalidouathanasia@gmail.com (A.T.); kkazeli@physics.auth.gr (K.K.)
² School of Physics, Faculty of Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
³ School of Veterinary Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; agkinou@vet.auth.gr
⁴ 5th Surgical Department, School of Medicine, Aristotle University of Thessaloniki, Ippokratio General Hospital, 54642 Thessaloniki, Greece; ariadnefou@gmail.com
⁵ Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; daoudaki@auth.gr
* Correspondence: evlimper@gmail.com or evlimper@ihu.gr

Abstract: Rheumatoid arthritis (RA) is a well-known autoimmune inflammatory disease that affects the diarthrodial joints. Inflammation increases the production of reactive oxygen species (ROS), which may explain why RA is one of the diseases that induce oxidative stress. This study aimed to evaluate the potential differences in biochemical, hematological, and oxidative stress markers in the early stages of RA and after different treatment regimens. The study involved 111 patients, 28 men and 83 women aged 34 to 59 years, who were divided based on their c-reactive protein (CRP) levels into inactive RA patients (IRA) with CRP < 1.3 (n = 57, 22 men and 35 women) and active RA patients (ARA) with CRP ≥ 1.3 (n = 54, 6 men and 48 women). The study participants were divided into two groups, A and B, based on their treatment regimen. Group A, 90% of which were IRA patients, received methotrexate (MTX) monotherapy. Group B, which comprised 90% ARA patients, received a combination of leflunomide, a conventional disease-modifying antirheumatic drug (DMARD), and a biologic DMARD. The hematological, biochemical, oxidative stress, and RA-specific biomarkers were measured twice in groups A and B in the early stage of the disease, before and 3 months post-treatment, using conventional colorimetric, fluorometric, and immunological assays. According to the results of our study, glutathione peroxidase (GPx), ROS, calcium (Ca) and phosphorus (P) ions, vitamin C and D, and lipid profiles could serve as potential diagnostic markers in the early stages of the disease. Both treatment options were equally effective at improving the overall health of the patients. However, treatment resulted in a further increase in ROS levels and a decrease in antioxidant markers.

Keywords: rheumatoid arthritis; oxidative stress markers; antioxidant markers; biochemical markers; methotrexate; DMARD; biological agents



Citation: Ioannidou, S.; Tsiakalidou, A.; Kazeli, K.; Ginoudis, A.; Fouza, A.; Daoudaki, M.; Lymperaki, E. Evaluation of Biochemical and Oxidative Stress Markers in the Early Stages of Rheumatoid Arthritis in a Comparative Study of Two Different Therapeutic Approaches. *Oxygen* **2024**, *4*, 253–265. <https://doi.org/10.3390/oxygen4030014>

Academic Editor: John T. Hancock

Received: 28 March 2024

Revised: 5 May 2024

Accepted: 24 June 2024

Published: 27 June 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disease affecting multiple systems, primarily joints [1,2]. Chronic inflammation replaces bone erosion through cartilage destruction [1–3]. The recent literature suggests that various pathogenetic mechanisms of RA involve immune system cells. CD4+ memory T cells present in tissue infiltrates or ectopic germinal centers stimulate B cells to proliferate, differentiate, and produce rheumatoid factor (RF) or ACPAs. In addition, the intima undergoes significant expansion due to the increased number and activation of macrophages, which secrete pro-inflammatory cytokines,

such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF)- α , which together with proteinases cause bone and cartilage damage [2,4,5].

Rheumatoid arthritis (RA) has two main subtypes, distinguished by the presence or absence of anti-citrullinated protein antibodies (ACPAs). Other autoimmune antibodies used in the diagnosis of RA are anti-nuclear antibodies (ANAs), anti-cyclic citrullinated peptides (anti-CCP), and RF [6–8]. During the early stages of RA, anti-CCP and RF may not be detectable in a significant percentage of patients and may remain undetectable in a small number of individuals throughout the course of the disease [9–11]. As a result, the 2010 Rheumatoid Arthritis Classification Criteria included additional markers for the early stages of RA, such as abnormal C-reactive protein (CRP) and/or abnormal erythrocyte sedimentation rate (ESR) [1,12,13]. Moreover, according to a recent bibliography, CRP is commonly considered to be an indicator of systemic inflammation in RA. However, it is also a regulator of the immune system. It plays an important role in the inflammatory pathways associated with RA [14,15].

RA is associated with the increased production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in response to inflammation, which leads to oxidative stress [16–18]. Antioxidants regulate potentially elevated levels of ROS/RNS during oxidative stress by scavenging them and inhibiting the oxidative process in cells [17,19,20]. Studies have shown that patients with active disease exhibit higher levels of ROS and lower antioxidant potential compared to healthy controls [17,19,21]. These findings have been confirmed in patients with RA through increased serum malondialdehyde (MDA) levels and decreased antioxidant enzyme activity, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) [22].

In RA, inflammation is also associated with changes in lipoprotein metabolism, particularly high-density lipoprotein cholesterol (HDL) [23–28]. Studies have suggested that people with RA may be at higher risk for cardiovascular disease (CVD) due to a decreased HDL production rate and an increased TG clearance rate, resulting in a high TG to HDL ratio [26,27,29–31]. Alterations in lipid metabolism may be both a cause and/or a consequence of RA. Due to conflicting results regarding lipid levels in RA caused by differences in population, study duration, and/or the analytical methods of lipid metabolism, investigating various types of lipids and their metabolites, such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and their derived oxylipins (resolvins, maresins), may clarify the interventional role of lipids in RA and guide therapeutic regimens [26,27].

The treatment regimens vary depending on the stage of the disease. In the case of RA patients, early treatment is recommended, as it has been associated with reduced progression of synovitis and bone erosions, as well as improved disability prognosis [32]. In the first-line treatment of RA, both disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX) and/or leflunomide (LEF), and biologic DMARDs are commonly used [2,33]. The most commonly used DMARD, MTX, works by releasing adenosine from fibroblasts. This reduces neutrophil adhesion, inhibits neutrophil leukotriene B₄ synthesis, local IL-1 production, and synovial collagenase gene expression, and reduces IL-6 and IL-8 levels. However, even at low doses, there is still a risk of significant liver damage as a side effect of methotrexate (MTX) treatment [32–35].

Due to the crucial and dynamic functions of calcium, magnesium, and phosphorus in maintaining bone tissue balance and managing inflammation [36,37], numerous studies have explored the potential benefits of magnesium, calcium, and vitamin D supplementation in conjunction with various therapies in RA [38–40]. Magnesium deficiency may promote the inflammatory process by prolonging the opening of calcium channels and activating N-methyl-D-aspartate receptors [39].

Based on the above, we conducted a study to examine the correlation between certain biochemical, hematological, and oxidative stress parameters and the specific markers of RA in the context of two different therapeutic regimens. We aimed to determine the relationship between these factors and RA treatment outcomes. As further clarification is needed on the

supplementation of Mg, Ca, and Vitamin D in RA patients, we included their blood levels in our study.

2. Materials and Methods

2.1. Study Population

The study cohort included 111 patients (28 men and 83 women) in the early stages of RA, aged between 34 and 59 years. All patients attended the rheumatology outpatient clinic at the General Hospital for the first time and fulfilled the American College of Rheumatology criteria for the classification of RA. Patients were selected based on screening assessments, including medical history, laboratory tests, and physical examination conducted by the rheumatologist due to joint pain, morning stiffness, and/or stiffness following periods of rest. Written informed consent was obtained from all patients, and the protocol was approved by the local ethics committee of the General Hospital. The patients were divided according to CRP levels into inactive RA patients (IRA) with $CRP < 1.3$ ($n = 57$, 22 men and 35 women) and active RA patients (ARA) with $CRP \geq 1.3$ ($n = 54$, 6 men and 48 women). All patients (IRA and ARA patients) were divided into two groups, A and B, based on treatment regimen. Group A, consisting of 90% IRA (inactive) patients, received MTX monotherapy, and Group B, consisting of 90% RA (active) patients, received a combination of a conventional DMARD, specifically leflunomide, with a biologic DMARD. (Figure 1). Specifically, Group A received 7.5 mg methotrexate (MTX) subcutaneously once a week. Group B underwent combination therapy; these patients were given a conventional modifying antirheumatic drug (DMARD) daily in combination with a biologic DMARD. In particular, Group B received a leflunomide (LEF) pill at 20 mg daily, and they received a Cimzia injection of 200 mg subcutaneously every 15 days.




Figure 1. Flowchart of study population.

Blood samples were collected before and after the 12-week treatment period. The demographic and clinical information, along with medical history details, were collected from all patients. Our study participants were not taking any medication or dietary supplements. Blood samples were collected between 8:00 and 9:00 a.m., centrifuged to isolate the serum and plasma samples from EDTA-treated blood, and stored at $-80\text{ }^{\circ}\text{C}$ until processed. Hemolyzed samples were excluded. Laboratory analyses were performed on patients before and after treatment. These included the following: Erythrocyte sedimentation rate (ESR), platelets (PLT), c-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptides (Anti-CCP), anti-nuclear antibodies (ANA), reactive oxygen species (ROS), glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD), gamma-glutamyl transferase (γ -GT), vitamin C (Vit C), vitamin D (Vit D), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), alkaline phosphatase (ALP), amylase (AMY), phosphorus (P), magnesium (Mg), and calcium (Ca).

2.2. Determination of Significant Markers for Rheumatoid Arthritis

The specific markers for RA—ANA, RF, CRP, and anti-CCP—were measured using the Roche Cobas E801 immunochemistry module (Roche, Basel, Switzerland). In particular, the determination of ANA was based on a standard indirect immunofluorescence (IIF) assay. RF was measured using a commercially available immunoturbidimetric assay. CRP (C-reactive protein) quantity was determined by Immunoturbidimetry. Anti-CCP assay was determined with a chemiluminescent microparticle immunoassay (CMIA).

2.3. Determination of Hematological Markers (ESR and PLT) and Serum Lipoproteins, Vitamins, Liver Enzymes, Amylase, and Electrolytes

An ESR hematology test was measured using the Westergren method, and PLT was determined using flow cytometry fluorescence.

All biochemical parameters (TC, HDL, LDL, TG, Vit D, Vit C, γ -GT, ALP, AMY, Ca, Mg, and P) were measured using colorimetric and enzymatic colorimetric assays on the Roche Cobas 8000 analyzer series, specifically the C702 clinical chemistry module and the E801 immunochemistry module. Vit C was measured photometrically.

2.4. Determination of Reactive Oxygen Species

ROS activity was measured fluorometrically (infinite 200 PRO, TECAN Trading AG, Männedorf, Switzerland). Specifically, the assay was performed using the reagent 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA), which measures the amount of H₂O₂ and other reactive oxygen species (ROS). The fluorescent intensity is proportional to the ROS level.

2.5. Determination of Antioxidants (GPx, CAT, and SOD)

GPx activity was measured indirectly by a coupled reaction with glutathione reductase (GR). Oxidized glutathione, produced by the reduction of hydrogen peroxide by GPx, is converted to its reduced state by GR and NADPH. The oxidation of NADPH to NADP⁺ is accompanied by a decrease in absorbance at 340 nm using the Elisa microplate reader. The decrease in NADPH measured at 340 nm is proportional to the GPx activity in the sample.

CAT activity was determined by measuring H₂O₂. Catalase catalyzes the decomposition of hydrogen peroxide. A decrease in the concentration of peroxide is accompanied by a decrease in absorbance at 240 nm.

A spectrophotometric method was used to determine SOD activity. The method is based on the xanthine/xanthine oxidase system, which produces superoxide that reduces nitrotetrazole blue to formazan. SOD inhibits the reaction and converts the superoxide to oxygen. The product is read at 550 nm using a Pharmacia Biotech Novaspec II spectrophotometer.

2.6. Statistical Analysis

The statistical analysis to calculate the means and correlations was performed using the SPSS tool version 22.0. The data were checked for normality, and appropriate statistical tests were chosen for analyses. We used the student *t*-test to investigate the relationship between the two groups before and after the implementation of the different therapeutic approaches for each of the measured parameters. Additionally, we used the Pearson Correlation Coefficient to measure the linear correlation between the groups and the Spearman Correlation when required. In all statistical analyses, the level of significance (*p*-value) was set at 0.001 and 0.05.

2.7. Ethical Considerations

The study was conducted in accordance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and the European General Regulation 2016/679 and law N.2472/1997. Ethical approval to perform this study was obtained from the Administration

and the Scientific Council of Hospital 638/412023. The confidentiality of the participants was strictly preserved, and personal privacy was fully respected.

3. Results

Table 1 shows the mean values of all biochemical and oxidative markers in the early stages of rheumatoid arthritis.

Table 1. Mean values of biomarkers according to their CRP values.

Biomarkers	Reference Range	Mean Values		p-Value
		IRA Patients CRP < 1.3	ARA Patients CRP ≥ 1.3	
ESR	0–18 mm/h	25.12	25.66	0.34521
PLT	130–400 10 ³ /mL	301.39	316.88	0.20711
CRP	0.08–0.8 mg/dL	0.95	8.03	<0.0001
RF	0–35 U/mL	43.97	49.07	0.14816
Anti-CCP	<12 U/mL	13.10	17.69	<0.0001
ANA	<1/100 U/mL	1/336	1/360	<0.0001
ROS	125 μM	68.71	61.49	0.20711
GPx	4.5–7.5 U/mg Hb	7.71	5.19	0.4916
CAT	10.5–13 U/mg Hb	11.50	11.67	0.10993
SOD	1.1–1.6 U/mg Hb	1.33	1.38	<0.05
γ-GT	5–50 U/L	137.53	180.14	<0.01
Vit C	0.6–2 mg/dL	0.34	0.34	0.43442
Vit D	30–100 ng/ml	15.47	14.83	0.19955
TC	120–200 mg/dL	195.82	189.50	<0.0001
TG	<150 mg/dL	180.50	188.25	0.21788
HDL	>40 mg/dL	39.37	38.94	0.41449
LDL	<150 mg/dL	197.82	193.28	0.29411
ALP	20–120 U/L	229.37	238.97	0.23571
AMY	40–140 U/L	202.39	215.11	0.13083
P	2.7–4.5 mg/dL	5.38	5.17	0.14323
Mg	1.9–3.1 mg/dL	1.35	1.36	0.42267
Ca	8.3–10.5 mg/dL	6.76	6.83	0.30546

Abbreviations in Table 1. ALP: alkaline phosphatase, Anti-CCP: anti-cyclic citrullinated peptide, AMY: amylase, ANA: anti-nuclear antibodies, ARA: active rheumatoid arthritis, Ca: calcium, CAT: catalase, CRP: c-reactive protein, ESR: erythrocyte sedimentation rate, γ-GT: gamma-glutamyl transferase, GPx: glutathione peroxidase, HDL: high-density lipoprotein, IRA: inactive rheumatoid arthritis, LDL: low-density lipoprotein, Mg: magnesium, P: phosphorus, PLT: platelets, RF: rheumatoid factor, ROS: reactive oxygen species, SOD: superoxide dismutase, TC: total cholesterol, TG: triglycerides Vit C: vitamin C, and Vit D: vitamin D.

The participants were divided into two groups based on their CRP values: 57 participants (22 men and 35 women) with CRP < 1.3 were identified as IRA, while 54 participants (6 men and 48 women) with CRP ≥ 1.3 were identified as ARA.

All biomarkers in the IRA and ARA patients showed deviant values compared to controls, except for PLTs, TC, ANA, CAT, and SOD. As expected, the ARA patients had statistically significantly higher mean values of CRP (8.03 mg/dL, $p < 0.0001$). Furthermore, the ARA patients exhibited significantly higher levels of anti-CCP (17.69 U/mL, $p < 0.0001$), γ-GT (180.14 U/L, $p < 0.01$), and SOD (1.38 U/mg Hb, $p < 0.05$). Additionally, lower levels of TC (189.50 mg/dL, $p < 0.0001$) and ANA (1/360 U/mL, $p < 0.0001$) were also observed.

The study found no statistically significant differences between the IRA and ARA patients in terms of the mean values of the following parameters: ROS (68.71 mM vs. 61.49 mM, $p = 0.2071$), HDL (39.37 mg/dL vs. 38.94 mg/dL, $p = 0.4145$), LDL-C (197.82 mg/dL vs. 193.28 mg/dL, $p = 0.2941$), P (5.38 mg/dL vs. 5.17 mg/dL, $p = 0.1432$), Vit D (15.47 ng/mL vs. 14.83 ng/mL, $p = 0.1995$), ESR (25.12 mm/h vs. 25.66 mm/h, $p = 0.3452$), RF (43.97 U/mL vs. 49.07 U/mL, $p = 0.1482$), PLTs (301.39 10³/μL vs. 316.88 10³/μL, $p = 0.2071$), and TG (180.50 mg/dL vs. 188.2 mg/dL, $p = 0.21788$), ALP (229.37 U/L vs. 238.97 U/L, $p = 0.2357$), AMY (202.39 U/L vs. 215.11 U/L, $p = 0.1308$), CAT (11.50 U/mg Hb vs. 11.67 U/mg Hb,

$p = 0.1099$), and Ca (6.76 mg/dL vs. 6.83, $p = 0.30546$), GPx (7.71 U/mgHb vs. 5.19 U/mgHb, $p = 0.4916$), Mg (1.35 mg/dL vs. 1.36 mg/dL, $p = 0.4227$), and Vit C (0.34 mg/dL vs. 0.34 mg/dL, $p = 0.4344$). The p -value for each parameter was greater than 0.05, indicating no significant difference.

Table 2 presents the mean values of all parameters in Group A (56 participants were treated with MTX monotherapy) and Group B (55 participants were treated with a combination of a conventional DMARD). No significant differences were observed when comparing the IRA and ARA patients in groups A and B. It is worth noting that in both groups A and B, the mean values of ESR, PLT, CRP, RF, Anti-CCP, ANA, GPx, CAT, SOD, γ -GT, ALP, TC, TG, LDL-C, ALP, AMY, and P decreased significantly, while the ROS, Vit C, Vit D, HDL-C, Mg, and Ca values increased significantly after treatment ($p < 0.0001$). Moreover, there was no difference between the two different treatments.

Table 2. Mean values of biomarkers in the early stages of RA and after the treatment with different therapeutic approaches.

Biomarkers	Reference Range	Group A *		Group B *	
		Before	After	Before	After
ESR	0–18 mm/h	25.62	13.39	25.14	14.30
PLT	130–400 $10^3/\mu\text{L}$	310.92	224.87	306.84	219.68
CRP	0.08–0.8 mg/dL	1.24	0.47	7.55	4.86
RF	0–35 U/mL	41.61	17.55	51.25	30.16
Anti-CCP	<12 U/mL	16.23	11.81	14.07	9.18
ANA	<1/100 U/mL	1/353	1/209	1/340	1/244
ROS	125 μM	62.48	119.97	68.93	128.41
GPx	4.5–7.5 U/mg Hb	5.08	3.08	5.29	2.95
CAT	10.5–13 U/mg Hb	11.56	8.65	11.58	8.71
SOD	1.1–1.6 U/mg Hb	1.38	0.83	1.33	0.85
γ -GT	5–50 U/L	143.18	47.47	171.14	101.03
Vit C	0.6–2 mg/dL	0.30	0.77	0.38	0.78
Vit D	30–100 ng/mL	15.58	33.95	14.73	37.46
TC	120–200 mg/dL	198.08	162.84	188.27	150.27
TG	<150 mg/dL	180.42	139.47	185.54	122.84
HDL	>40 mg/dL	40.68	56.11	38.11	60.54
LDL	<150 mg/dL	194.84	114.29	198.86	119.57
ALP	20–120 U/L	232.92	100.00	235.86	139.11
AMY	40–140 U/L	212.03	112.32	204.46	121.38
P	2.7–4.5 mg/dL	5.33	3.71	5.25	3.51
Mg	1.9–3.1 mg/dL	1.32	1.98	1.38	2.15
Ca	8.3–10.5 mg/dL	6.85	8.99	6.73	8.77

Abbreviations of Table 2. ALP: alkaline phosphatase, Anti-CCP: anti-cyclic citrullinated peptide, AMY: amylase, ANA: anti-nuclear antibodies, Ca: calcium, CAT: catalase, CRP: c-reactive protein, ESR: erythrocyte sedimentation rate, γ -GT: gamma-glutamyl transferase, GPx: glutathione peroxidase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, Mg: magnesium, P: phosphorus, PLT: platelets, RF: rheumatoid factor, ROS: reactive oxygen species, SOD: superoxide dismutase, TC: total cholesterol, TG: triglycerides Vit C: vitamin C, and Vit D: vitamin D. * $p < 0.0001$.

Table 3 presents the correlation between the biochemical and oxidative stress markers and the specific markers of RA before and after two different treatments in patients with rheumatoid arthritis. In the early stages of the disease, glutathione peroxidase (GPx) shows a positive correlation with CRP ($r = 0.261$), RF ($r = 0.137$), and anti-CCP ($r = 0.162$). After treatment, total cholesterol (TC) is negatively correlated with CRP ($r = -0.157$) and RF ($r = -0.333$). At this phase, HDL-C shows a positive correlation with CRP ($r = 0.297$) and RF ($r = 0.142$). Vitamin C showed a positive correlation with CRP before ($r = 0.291$) and after treatment ($r = 0.354$). No statistically significant correlations were observed between the other biomarkers and the specific markers of RA.

Table 3. Correlation of biomarkers with specific markers of RA before and after the treatment.

Biomarkers	Before Therapy					After Therapy				
	PLT	CRP	RF	Anti-CCP	ANA	PLT	CRP	RF	Anti-CCP	ANA
ROS	-0.123	-0.081	-0.020	0.154	0.105	0.079	-0.026	0.080	-0.033	-0.027
GPx	0.029	0.261	0.137	0.162	-0.034	-0.146	-0.030	-0.078	-0.071	-0.091
CAT	0.157	0.202	-0.055	0.107	-0.210	-0.140	0.111	0.018	-0.163	-0.083
SOD	0.107	-0.050	-0.051	0.156	-0.277	0.037	-0.049	0.030	0.170	-0.261
γ-GT	0.032	0.083	0.061	0.267	-0.006	0.128	0.159	0.150	0.101	-0.193
Vit C	0.025	0.291	0.024	-0.008	-0.070	0.112	0.354	0.051	0.271	-0.069
Vit D	0.010	-0.163	-0.154	0.072	-0.046	-0.090	-0.022	-0.041	0.091	0.106
TC	0.069	-0.052	-0.265	0.079	0.064	-0.053	-0.157	-0.333	0.050	0.139
TG	0.017	0.106	-0.070	0.106	-0.080	-0.099	-0.264	-0.174	0.061	0.134
HDL	-0.162	0.100	0.079	-0.069	0.125	-0.203	0.297	0.142	-0.122	0.028
LDL	0.008	-0.04	-0.086	-0.162	0.076	0.119	-0.003	0.050	-0.183	0.265
ALP	0.055	0.072	0.064	0.195	-0.185	-0.045	0.210	0.182	0.076	-0.268
AMY	-0.028	0.174	-0.168	0.176	0.096	-0.093	0.123	-0.079	0.009	0.097
P	0.111	-0.066	0.026	0.175	0.317	0.094	0.112	0.023	0.332	0.200
Mg	-0.072	-0.048	-0.045	0.172	-0.026	-0.017	-0.012	0.161	0.143	-0.082
Ca	-0.174	-0.102	0.118	0.024	-0.034	-0.205	-0.193	-0.031	0.160	0.025

Abbreviations of Table 3. ALP: alkaline phosphatase, Anti-CCP: anti-cyclic citrullinated peptide, AMY: amylase, ANA: anti-nuclear antibodies, Ca: calcium, CAT: catalase, CRP: c-reactive protein, γ-GT: gamma-glutamyl transferase, GPx: glutathione peroxidase, HDL: high-density lipo-protein, LDL: low-density lipoprotein, Mg: magnesium, P: phosphorus, PLT: platelets, RF: rheumatoid factor, ROS: reactive oxygen species, SOD: superoxide dismutase, TC: total cholesterol, TG: triglycerides Vit C: vitamin C, and Vit D: vitamin D.

4. Discussion

Our study shows that biochemical and oxidative stress markers, in conjunction with certain RA markers, hold promise as prognostic biomarkers during the inactive phase of the disease. Our study observed the impact of two different therapeutic approaches on biomarkers, which may have implications for the management of potential outcomes of rheumatoid arthritis.

Recent studies suggest that patients with RA may experience tissue damage due to oxidative stress caused by increased ROS generation, lipid peroxidation, protein oxidation, DNA damage, and decreased antioxidant activity [19,20,41]. Although there are conflicting views, one study found that patients with active RA had higher levels of oxidative status and increased antioxidant activity compared to healthy subjects. However, the levels of antioxidants have been found to be insufficient to effectively mitigate oxidative damage [11]. Our study found that participants with inactive RA had high oxidative stress and low antioxidants, as indicated by the CAT and SOD levels, which promote the disease's oxidative process. Meanwhile, the GPx levels were elevated, possibly because of the protective role of GPx against ROS, especially in this phase of the disease.

Significantly elevated values of TC, TG, and LDL were also observed. The results could be attributed to lipid peroxidation and oxidized lipids, such as arachidonic acid, prostaglandin, thromboxane, and leukotriene. These are primarily considered to be substrates for the pro-inflammatory process [26]. In contrast, lipoxins are anti-inflammatory and pro-resolving molecules that help reduce inflammation and restore tissue homeostasis [26,42].

Moreover, our results are in line with a previous study that demonstrated increased levels of ALP and γ-GT in RA patients with inflammation [37]. Furthermore, elevated serum levels of amylase were found in the early stages of the disease. Another study suggested that salivary AMY concentration was also elevated in RA patients, suggesting the potential use of AMY as an early diagnostic marker [43].

The data indicate that there is a change in calcium and phosphorus metabolism in RA [44,45]. A recent study found that serum calcium levels and the ratio of calcium to phosphorus were reduced, whereas serum phosphorus levels increased in patients with inactive RA [45]. A study has suggested that serum phosphorus levels could be used as a prognostic indicator of RA disease activity, even in those with subclinical activity [44]. This is particularly true for inactive RA patients, as higher levels of serum P and lower levels

of Ca were observed in them compared to active RA patients. These findings support our results. Therefore, serum P and Ca, along with the specific markers of RA, could be used as potential prognostic biomarkers. During the active phase of RA, there is a continuous inflammatory process, resulting in an increase in inflammation-related biomarkers such as CRP and ESR, as well as RA-specific markers, including RF, anti-CCP, and ANA. These biomarkers indicate the immune system's response to the general inflammation associated with the disease. In patients with autoimmune RA, inflammation appears to be acutely associated with an imbalance in oxidative stress status and antioxidant systems [16,17].

During the active phase of the disease, certain antioxidant genes are activated to neutralize high levels of ROS and preserve the redox balance. This study showed that the activation of the GPx3 gene reduced extracellular ROS levels, indicating the antioxidant protective effect of GPx on cells against oxidative damage. According to a previous study, the activation of the gene GPx3 reduces the levels of extracellular ROS, which ultimately proves the protective antioxidant effect of GPx in cells against oxidative damage [46]. Gonzalez et al. (2015) investigated changes in protein carbonyl levels, superoxide dismutase, glutathione peroxidase activity, glutathione concentration, and the glutathione/oxidized glutathione ratio in RA patients and healthy participants. The study found that although patients with active RA had higher levels of SOD and GPx activity, these levels were not sufficient to prevent oxidation damage to lipids and proteins [11]. Our study supports these findings. The ROS values decreased while antioxidants, such as GPx, CAT, and SOD, increased, possibly due to the anti-inflammatory response to the primary inflammation of the disease [47].

During this phase of the disease, we found a positive correlation between GPx and CRP ($r = 0.261$), RF ($r = 0.137$), and anti-CCP ($r = 0.162$) in our patients. GPx plays a protective role against oxidation and primary inflammation [48]. It could potentially be used as a diagnostic marker in combination with specific markers for RA. Recent studies have investigated the relationship between changes in serum lipid levels in RA patients before and after treatment [21,26,49]. During the active phase of the disease, some studies have observed elevated levels of LDL and TG, and HDL levels decreased [50–52]. These findings are consistent with our results. In particular, we found that all RA patients had significantly high levels of TC, TG, and LDL before the onset of RA, whereas the levels of HDL were low.

A decrease in serum levels of Vit C and Vit D has been observed [53], and, as they are thought to have immunomodulatory and anti-inflammatory properties, their deficiency in RA patients may contribute to the progression or severity of the disease. Low levels of vitamin D may be associated with increased immune activation, as noted in several studies [53–55], one of which showed that patients with high disease activity had lower vitamin D levels than those with moderate or low disease activity [56]. Vitamin C has been shown to have strong antioxidant and anti-inflammatory effects [57–59]. The possible etiological cause of vitamin deficiency may be related to the body's use of vitamins in response to inflammatory processes. Our study provides statistical evidence that both vitamin C and vitamin D levels increased after both types of treatment, which contributes to a reduction in the inflammation level. The mechanism of their action is currently under investigation in our laboratory. Our findings indicate an improvement in vitamin C and D deficiencies following the treatment, compared to their pre-treatment levels.

In recent years, combinations of conventional DMARD with biologic DMARD have been used to treat patients with RA. Methotrexate (MTX) is one of the most commonly used and effective conventional DMARDs due to its ability to stabilize low-level disease activity. Katturajan et al. (2021) found that MTX inhibits methionine production, leading to hyperhomocysteinemia and intracellular oxidative stress. This oxidative stress inhibits the initiation of DNA binding by nuclear factor erythroid 2-related factor 2, which encodes antioxidant genes, particularly γ -gcs, through silent mating-type information regulation-2 homolog. As a result, tissue damage is prevented, and glutathione synthesis is inhibited [60]. MTX-induced toxicity is associated with glutathione depletion, resulting in oxidative stress

due to reduced antioxidant capacity [61]. In our study, after 3 months of treatment, the levels of ROS values continued to increase in both treatment groups, while the values of antioxidant markers (GPx, CAT, and SOD) decreased. This may be due to the mechanism of MTX action, which is dependent on the generation of ROS and requires further investigation. Several studies have observed an association between thrombocytopenia and MTX treatment [62,63]. Increased levels of ROS are responsible for premature platelet apoptosis [64,65]. A recent study found that MTX caused a significant release of Ca²⁺ from the endoplasmic reticulum, and an analysis of eIF2- α immunoblots indicated that PLT is exposed to endoplasmic reticulum stress during MTX treatment [62]. This study supports our findings, as we also observed a decrease in PLT levels in both groups after treatment with DMARD. The decrease in PLT levels appears to be related to PLT apoptosis, which is caused by the mechanism of MTX action, which depends on the production of ROS.

Inflammation-related biomarkers and RA-specific markers were found to be regulated to normal levels at this stage. We also observed that the imbalanced lipid levels were under the influence of disease medications, which may be due to the important role of lipoxins in reducing inflammation. The vitamin deficiencies were also treated without the use of supplements, suggesting that both treatment options were equally effective in improving the patient's blood lipid levels and their overall health. Patients should be encouraged to test their biomarkers frequently to help prevent comorbidities and drug toxicity and to help manage their disease.

5. Conclusions

Based on our results, GPx could be used as a potential diagnostic marker when combined with other biomarkers such as ROS, Ca, P, Vit C, Vit D, and lipid profile due to their alterations in the early inactive phase of the disease. The general state of patients' health improved after 3 months of treatment regimens. Both treatment options were equally effective and did not influence redox status parameters differently. After the treatment, ROS levels continued to increase while antioxidant markers decreased. This may be attributed to the mechanism of DMARD action, which depends on the generation of ROS. In order to ensure that the treatment remains effective in regulating patients' oxidative stress, future studies on antioxidant supplementation in personalized medicine should be conducted before or after the treatment.

Author Contributions: Conceptualization, E.L.; methodology, K.K.; validation, S.I., A.T. and E.L.; formal analysis, S.I. and E.L.; investigation, S.I., A.T., K.K., A.G. and E.L.; data curation, S.I., K.K., A.G., A.F. and M.D.; writing—original draft preparation, S.I.; writing—review and editing, K.K., A.G., A.F., M.D. and E.L.; visualization, S.I., K.K. and E.L.; supervision, E.L.; project administration, E.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and the European General Regulation 2016/679 and law N.2472/1997. Ethical approval to perform this study was obtained from the Administration and the Scientific Council of Hospital 638/412023).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No data are available due to privacy or ethical restrictions.

Acknowledgments: We acknowledge and thank the contribution of all the doctors, nurses, and other members of the outpatient Clinic of the General Hospital of Greece who were involved in the care of the patients and the collection of the blood samples but who are not listed as authors.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

ACPAs	anti-citrullinated protein antibodies
ALP	alkaline phosphatase
AMY	Amylase
ANA	anti-nuclear antibodies
Anti-CCP	anti-cyclic citrullinated peptide
ARA	active rheumatoid arthritis
Ca	Calcium
CAT	Catalase
CRP	c-reactive protein
CVD	cardiovascular disease
DHA	docosahexaenoic acid
DMARD	disease-modifying antirheumatic drugs
EPA	eicosapentaenoic acid
ESR	erythrocyte sedimentation rate
γ-GT	gamma-glutamyl transferase
GPx	glutathione peroxidase
GR	glutathione reductase
HDL	high-density lipoprotein
H2DCFDA	2', 7'-dichlorodihydrofluorescein diacetate
H2O2	hydrogen peroxide
IIF	indirect immunofluorescence
IL-1	interleukin-1
IL-6	interleukin-6
IL-8	interleukin-8
IRA	inactive rheumatoid arthritis
LDL	low-density lipoprotein
LEF	Leflunomide
MDA	Malondialdehyde
Mg	Magnesium
MTX	Methotrexate
NADPH	nicotinamide adenine dinucleotide phosphate
P	Phosphorus
PLT	Platelets
RA	rheumatoid arthritis
RF	rheumatoid factor
RNS	reactive nitrogen species
ROS	reactive oxygen species
SOD	superoxide dismutase
TC	total cholesterol
TG	Triglycerides
TNF	tumor necrosis factor
TOS	total oxidative status
Vit C	vitamin C
Vit D	vitamin D

References

1. Lin, Y.-J.; Anzaghe, M.; Schülke, S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. *Cells* **2020**, *9*, 880. [[CrossRef](#)]
2. Yap, H.-Y.; Tee, S.Z.-Y.; Wong, M.M.-T.; Chow, S.-K.; Peh, S.-C.; Teow, S.-Y. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. *Cells* **2018**, *7*, 161. [[CrossRef](#)]
3. Nanke, Y. The Pathogenesis of Rheumatoid Arthritis Breakthroughs in Molecular Mechanisms 1 and 2. *Int. J. Mol. Sci.* **2023**, *24*, 11060. [[CrossRef](#)]
4. Jang, S.; Kwon, E.-J.; Lee, J.J. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. *Int. J. Mol. Sci.* **2022**, *23*, 905. [[CrossRef](#)] [[PubMed](#)]
5. Cajas, L.J.; Casallas, A.; Medina, Y.F.; Quintana, G.; Rondón, F. Pannus and rheumatoid arthritis: Historic and pathophysiological evolution. *Rev. Colomb. Reumatol.* **2019**, *26*, 118–128. [[CrossRef](#)]

6. Van Boekel, M.A.M.; Vossenaar, E.R.; Van Den Hoogen, F.H.J.; Van Venrooij, W.J. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. *Arthritis Res.* **2002**, *4*, 87. [[CrossRef](#)] [[PubMed](#)]
7. Conti, V.; Corbi, G.; Costantino, M.; De Bellis, E.; Manzo, V.; Sellitto, C.; Stefanelli, B.; Colucci, F.; Filippelli, A. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics. *Biomolecules* **2020**, *10*, 1672. [[CrossRef](#)] [[PubMed](#)]
8. Paknikar, S.S.; Crowson, C.S.; Davis, J.M.; Thanarajasingam, U. Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients with Rheumatoid Arthritis. *ACR Open Rheumatol.* **2021**, *3*, 422. [[CrossRef](#)] [[PubMed](#)]
9. Venables, P.; Maini, R.N. Diagnosis and differential diagnosis of rheumatoid arthritis. *UpToDate* 2012.
10. Braschi, E.; Shojania, K.; Michael Allan, G. Anti-CCP: A truly helpful rheumatoid arthritis test? *Can. Fam. Physician* **2016**, *62*, 234.
11. García-González, A.; Gaxiola-Robles, R.; Zenteno-Savín, T. Oxidative stress in patients with rheumatoid arthritis. *Rev. Invest. Clin.* **2015**, *67*, 46–53. [[CrossRef](#)]
12. Atzeni, F.; Talotta, R.; Masala, I.F.; Bongiovanni, S.; Boccassini, L.; Sarzi-Puttini, P. Biomarkers in Rheumatoid Arthritis. *Cureus* **2021**, *13*, 512–516. [[CrossRef](#)]
13. Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., 3rd; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* **2010**, *62*, 2569–2581. [[CrossRef](#)]
14. Fang, Z.; Lv, J.; Wang, J.; Qin, Q.; He, J.; Wang, M.; Zhou, G.; Liu, G.; Zhong, F.; Zheng, Y.; et al. C-Reactive Protein Promotes the Activation of Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis. *Front. Immunol.* **2020**, *11*, 958. [[CrossRef](#)]
15. Pope, J.E.; Choy, E.H. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. *Semin. Arthritis Rheum.* **2021**, *51*, 219–229. [[CrossRef](#)]
16. Ramos-González, E.; Bitzer-Quintero, O.; Ortiz, G.; Hernández-Cruz, J.; Ramírez-Jirano, L. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. *Neurologia* **2024**, *39*, 292–301. [[CrossRef](#)] [[PubMed](#)]
17. da Fonseca, L.J.S.; Nunes-Souza, V.; Goulart, M.O.F.; Rabelo, L.A. Oxidative Stress in Rheumatoid Arthritis: What the Future Might Hold regarding Novel Biomarkers and Add-On Therapies. *Oxid. Med. Cell Longev.* **2019**, *2019*, 7536805. [[CrossRef](#)]
18. Smallwood, M.J.; Nissim, A.; Knight, A.R.; Whiteman, M.; Haigh, R.; Winyard, P.G. Oxidative stress in autoimmune rheumatic diseases. *Free Radic. Biol. Med.* **2018**, *125*, 3–14. [[CrossRef](#)]
19. Mateen, S.; Moin, S.; Khan, A.Q.; Zafar, A.; Fatima, N. Increased Reactive Oxygen Species Formation and Oxidative Stress in Rheumatoid Arthritis. *PLoS ONE* **2016**, *11*, e0152925. [[CrossRef](#)] [[PubMed](#)]
20. Ponist, S.; Zloh, M.; Bauerova, K. Impact of Oxidative Stress on Inflammation in Rheumatoid and Adjuvant Arthritis: Damage to Lipids, Proteins, and Enzymatic Antioxidant Defense in Plasma and Different Tissues. In *Animal Models in Medicine and Biology*; IntechOpen: London, UK, 2019. [[CrossRef](#)]
21. Quiñonez-Flores, C.M.; González-Chávez, S.A.; Del Río Nájera, D.; Pacheco-Tena, C. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. *Biomed. Res. Int.* **2016**, *2016*, 6097417. [[CrossRef](#)]
22. Jewad, A.M.; Mahdi, J.K.; Kassim, M.N. Oxidative Stress Status in Patients with Rheumatoid Arthritis. *Univ. Thi-Qar J. Med.* **2019**, *17*, 135–144. [[CrossRef](#)]
23. Navarro-Millán, I.; Charles-Schoeman, C.; Yang, S.; Bathon, J.M.; Bridges, S.L.; Chen, L.; Cofield, S.S.; Dell'Italia, L.J.; Moreland, L.W.; O'Dell, J.R.; et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial. *Arthritis Rheum.* **2013**, *65*, 1430–1438. [[CrossRef](#)] [[PubMed](#)]
24. Charles-Schoeman, C.; Lee, Y.Y.; Shahbazian, A.; Wang, X.; Elashoff, D.; Curtis, J.R.; Navarro-Millán, I.; Yang, S.; Chen, L.; Cofield, S.S.; et al. Improvement of High-Density Lipoprotein Function in Patients with Early Rheumatoid Arthritis Treated with Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. *Arthritis Rheumatol.* **2017**, *69*, 46–57. [[CrossRef](#)] [[PubMed](#)]
25. Charles-Schoeman, C.; Wang, X.; Lee, Y.Y.; Shahbazian, A.; Navarro-Millán, I.; Yang, S.; Chen, L.; Cofield, S.S.; Moreland, L.W.; O'Dell, J.; et al. Association of Triple Therapy with Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheumatol.* **2016**, *68*, 577–586. [[CrossRef](#)] [[PubMed](#)]
26. Lei, Q.; Yang, J.; Li, L.; Zhao, N.; Lu, C.; Lu, A.; He, X. Lipid metabolism and rheumatoid arthritis. *Front. Immunol.* **2023**, *14*, 1190607. [[CrossRef](#)]
27. Liao, K.P.; Playford, M.P.; Frits, M.; Coblyn, J.S.; Iannaccone, C.; Weinblatt, M.E.; Shadick, N.S.; Mehta, N.N. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. *J. Am. Heart Assoc.* **2015**, *4*, e001588. [[CrossRef](#)] [[PubMed](#)]
28. Svenson, K.L.G.; Lithell, H.; Hällgren, R.; Selinus, I.; Vessby, B. Serum Lipoprotein in Active Rheumatoid Arthritis and Other Chronic Inflammatory Arthritides: I. Relativity to Inflammatory Activity. *Arch. Intern. Med.* **1987**, *147*, 1912–1916. [[CrossRef](#)] [[PubMed](#)]
29. Kim, J.-Y.; Lee, E.-Y.; Park, J.K.; Song, Y.W.; Kim, J.R.; Cho, K.-H. Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process. *PLoS ONE* **2016**, *11*, e0164564. [[CrossRef](#)]

30. Fernández-Ortiz, A.M.; Ortiz, A.M.; Pérez, S.; Toledano, E.; Abásolo, L.; González-Gay, M.A.; Castañeda, S.; González-Álvarez, I. Effects of disease activity on lipoprotein levels in patients with early arthritis: Can oxidized LDL cholesterol explain the lipid paradox theory? *Arthritis Res. Ther.* **2020**, *22*, 213. [[CrossRef](#)]
31. Dursunoğlu, D.; Evrengül, H.; Polat, B.; Tanrıverdi, H.; Çobankara, V.; Kaftan, A.; Kılıç, M. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. *Rheumatol. Int.* **2005**, *25*, 241–245. [[CrossRef](#)]
32. Benjamin, O.; Bansal, P.; Goyal, A.; Lappin, S.L. *Disease-Modifying Antirheumatic Drugs (DMARD)*; StatPearls: Boston, MA, USA, 2023.
33. Hu, Q.; Wang, H.; Xu, T. Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning. *J. Clin. Med.* **2023**, *12*, 1599. [[CrossRef](#)]
34. Karlsson Sundbaum, J.; Eriksson, N.; Hallberg, P.; Lehto, N.; Wadelius, M.; Baecklund, E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. *Int. J. Rheum. Dis.* **2019**, *22*, 1226–1232. [[CrossRef](#)]
35. Xin, D.; Li, H.; Zhou, S.; Zhong, H.; Pu, W. Effects of Anthraquinones on Immune Responses and Inflammatory Diseases. *Molecules* **2022**, *27*, 3831. [[CrossRef](#)]
36. Klein, G.L. The Role of Calcium in Inflammation-Associated Bone Resorption. *Biomolecules* **2018**, *8*, 69. [[CrossRef](#)]
37. Ciosek, Z.; Kot, K.; Kosik-Bogacka, D.; Łanocha-Arendarczyk, N.; Rotter, I. The Effects of Calcium, Magnesium, Phosphorus, Fluoride, and Lead on Bone Tissue. *Biomolecules* **2021**, *11*, 506. [[CrossRef](#)]
38. Wu, C.-Y.; Yang, H.-Y.; Luo, S.-F.; Huang, J.-L.; Lai, J.-H. Vitamin D Supplementation in Patients with Juvenile Idiopathic Arthritis. *Nutrients* **2022**, *14*, 1538. [[CrossRef](#)]
39. Tarleton, E.K.; Kennedy, A.G.; Rose, G.L.; Littenberg, B. Relationship between Magnesium Intake and Chronic Pain in U.S. Adults. *Nutrients* **2020**, *12*, 2104. [[CrossRef](#)]
40. Nakamura, Y.; Suzuki, T.; Yoshida, T.; Yamazaki, H.; Kato, H. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. *Nutrients* **2017**, *9*, 428. [[CrossRef](#)]
41. Desai, P.B.; Manjunath, S.; Kadi, S.; Chetana, K.; Vanishree, J. Oxidative stress and enzymatic antioxidant status in rheumatoid arthritis: A case control study. *Eur. Rev. Med. Pharmacol. Sci.* **2010**, *14*, 959–967.
42. Chandrasekharan, J.A.; Sharma-Wali, N. Lipoxins: Nature’s way to resolve inflammation. *J. Inflamm. Res.* **2015**, *8*, 181. [[CrossRef](#)]
43. Pakravan, F.; Isfahani, M.; Ghorbani, M.; Salesi, N.; Salesi, M. The salivary alpha-amylase concentration in patients with rheumatoid arthritis: A case-control study. *Dent. Res. J.* **2023**, *20*, 43.
44. Mohamed, S.B.; Elkenawy, M.F.; Elsaid, T.O.; Mashaly, G.E.-S. Serum substance P level as a marker for subclinical rheumatoid arthritis activity. *Egypt. J. Basic. Appl. Sci.* **2023**, *10*, 1–10. [[CrossRef](#)]
45. Jambale, T.A.; Halyal, S. Study of serum calcium/ phosphorus in rheumatoid arthritis patients. *Int. J. Clin. Biochem. Res.* **2017**, *4*, 103–105.
46. Chen, T.; Zhou, Z.; Peng, M.; Hu, H.; Sun, R.; Xu, J.; Zhu, C.; Li, Y.; Zhang, Q.; Luo, Y.; et al. Glutathione peroxidase 3 is a novel clinical diagnostic biomarker and potential therapeutic target for neutrophils in rheumatoid arthritis. *Arthritis Res. Ther.* **2023**, *25*, 66. [[CrossRef](#)]
47. Phillips, D.C.; Woollard, K.J.; Griffiths, H.R. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. *Br. J. Pharmacol.* **2003**, *138*, 501–511. [[CrossRef](#)]
48. Jacobson, G.A.; Ives, S.J.; Narkowicz, C.; Jones, G. Plasma glutathione peroxidase (GSH-Px) concentration is elevated in rheumatoid arthritis: A case-control study. *Clin. Rheumatol.* **2012**, *31*, 1543–1547. [[CrossRef](#)]
49. Dessie, G.; Tadesse, Y.; Genet, S.; Demelash, B. Assessment of serum lipid profiles and high-sensitivity c-reactive protein among patients suffering from rheumatoid arthritis at tikur anbessa specialized hospital, addis ababa, ethiopia: A cross-sectional study. *Open Access Rheumatol.* **2020**, *12*, 223–232. [[CrossRef](#)]
50. Mullick, O.S.; Bhattacharya, R.; Bhattacharyya, K.; Sarkar, R.N.; Das, A.; Chakraborty, D.; Sarkar, A.; Das, A. Lipid profile and its relationship with endothelial dysfunction and disease activity in patients of early Rheumatoid Arthritis. *Indian. J. Rheumatol.* **2014**, *9*, 9–13. [[CrossRef](#)]
51. Dessie, G. Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa. *PLoS ONE* **2022**, *17*, e0269431. [[CrossRef](#)]
52. Chavan, V.U.; Ramavaram, D.; Patel, P.A.; Rupani, M.P. Evaluation of Serum Magnesium, Lipid Profile and Various Biochemical Parameters as Risk Factors of Cardiovascular Diseases in Patients with Rheumatoid Arthritis. *J. Clin. Diagn. Res.* **2015**, *9*, BC01. [[CrossRef](#)]
53. Meena, N.; Singh Chawla, S.P.; Garg, R.; Batta, A.; Kaur, S. Assessment of Vitamin D in Rheumatoid Arthritis and Its Correlation with Disease Activity. *J. Nat. Sci. Biol. Med.* **2018**, *9*, 54. [[CrossRef](#)]
54. Bragazzi, N.L.; Watad, A.; Neumann, S.G.; Simon, M.; Brown, S.B.; Abu Much, A.; Harari, A.; Tiosano, S.; Amital, H.; Shoenfeld, Y. Vitamin D and rheumatoid arthritis: An ongoing mystery. *Curr. Opin. Rheumatol.* **2017**, *29*, 378–388. [[CrossRef](#)]
55. Merlino, L.A.; Curtis, J.; Mikuls, T.R.; Cerhan, J.R.; Criswell, L.A.; Saag, K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. *Arthritis Rheum.* **2004**, *50*, 72–77. [[CrossRef](#)]
56. Attar, S.M. Vitamin D deficiency in rheumatoid arthritis. Prevalence and association with disease activity in Western Saudi Arabia. *Saudi Med. J.* **2012**, *33*, 520–5. [[PubMed](#)]

57. Gegotek, A.; Skrzydlewska, E. Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid. *Antioxidants* **2022**, *11*, 1993. [[CrossRef](#)]
58. Gomathi, A.; Chenthamarai, G.; Manvizhi, S.; Gowrithilagam, T.G. Effects of Vitamin C and Vitamin E in rheumatoid arthritis-A randomized, open label, and comparative study in a tertiary care hospital. *Natl. J. Physiol. Pharm. Pharmacol.* **2022**, *12*, 9. [[CrossRef](#)]
59. Pattison, D.J.; Silman, A.J.; Goodson, N.J.; Lunt, M.; Bunn, D.; Luben, R.; Welch, A.; Bingham, S.; Khaw, K.-T.; Day, N.; et al. Vitamin C and the risk of developing inflammatory polyarthritis: Prospective nested case-control study. *Ann. Rheum. Dis.* **2004**, *63*, 843. [[CrossRef](#)]
60. Katturajan, R.; Vijayalakshmi, S.; Rasool, M.; Prince, S.E. Molecular toxicity of methotrexate in rheumatoid arthritis treatment: A novel perspective and therapeutic implications. *Toxicology* **2021**, *461*, 152909. [[CrossRef](#)]
61. Schmidt, S.; Messner, C.J.; Gaiser, C.; Hämmerli, C.; Suter-Dick, L. Methotrexate-Induced Liver Injury Is Associated with Oxidative Stress, Impaired Mitochondrial Respiration, and Endoplasmic Reticulum Stress In Vitro. *Int. J. Mol. Sci.* **2022**, *23*, 15116. [[CrossRef](#)]
62. Paul, M.; Hemshekhar, M.; Thushara, R.M.; Sundaram, M.S.; NaveenKumar, S.K.; Naveen, S.; Devaraja, S.; Somyajit, K.; West, R.; Basappa; et al. Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide. *PLoS ONE* **2015**, *10*, e0127558. [[CrossRef](#)]
63. Franck, H.; Rau, R.; Herborn, G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. *Clin. Rheumatol.* **1996**, *15*, 266–270. [[CrossRef](#)] [[PubMed](#)]
64. Wang, Z.; Cai, F.; Chen, X.; Luo, M.; Hu, L.; Lu, Y. The role of mitochondria-derived reactive oxygen species in hyperthermia-induced platelet apoptosis. *PLoS ONE* **2013**, *8*, e75044. [[CrossRef](#)] [[PubMed](#)]
65. Girish, K.S.; Paul, M.; Thushara, R.M.; Hemshekhar, M.; Shanmuga Sundaram, M.; Rangappa, K.S.; Kemparaju, K. Melatonin elevates apoptosis in human platelets via ROS mediated mitochondrial damage. *Biochem. Biophys. Res. Commun.* **2013**, *438*, 198–204. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.